Deciphera Pharmaceuticals

OverviewSuggest Edit

Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company. It develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies.
TypePublic
Founded2003
HQWaltham, MA, US
Websitedeciphera.com
Employee Ratings4

Latest Updates

Employees (est.) (Nov 2017)43(+8%)
Job Openings39
Share Price (May 2021)$34.3(-24%)
Cybersecurity ratingBMore

Key People/Management at Deciphera Pharmaceuticals

Michael D. Taylor

Michael D. Taylor

Director
Steven L. Hoerter

Steven L. Hoerter

President & CEO, Director
Daniel L. Flynn

Daniel L. Flynn

Executive Vice President, Chief Scientific Officer and Founder
Jeff Held

Jeff Held

Senior Vice President, General Counsel
Caroline Chevalier

Caroline Chevalier

Vice President, Human Resources
Tucker Kelly

Tucker Kelly

Executive Vice President, Chief Financial Officer and Treasurer
Show more

Deciphera Pharmaceuticals Office Locations

Deciphera Pharmaceuticals has offices in Waltham and Lawrence
Waltham, MA, US (HQ)
10 CityPoint, 500 Totten Pond Rd 6th Floor
Lawrence, KS, US
643 Massachusetts St #200
Waltham, MA, US
200 Smith St
Show all (3)

Deciphera Pharmaceuticals Financials and Metrics

Deciphera Pharmaceuticals Revenue

USD

Net income (Q3, 2017)

(12.0m)

EBIT (Q3, 2017)

(12.2m)

Market capitalization (7-May-2021)

2.0b

Closing stock price (7-May-2021)

34.3

Cash (30-Sept-2017)

82.1m
Deciphera Pharmaceuticals's current market capitalization is $2 b.
Annual
USDFY, 2015FY, 2016

General and administrative expense

5.1m5.7m

R&D expense

12.5m20.2m

Operating expense total

17.6m25.8m

EBIT

(17.6m)(25.8m)
Quarterly
USDQ3, 2016Q3, 2017

General and administrative expense

1.4m2.4m

R&D expense

4.7m9.8m

Operating expense total

6.1m12.2m

EBIT

(6.1m)(12.2m)
Annual
USDFY, 2015FY, 2016

Cash

25.8m57.5m

Prepaid Expenses

606.0k791.0k

Current Assets

26.4m58.3m

PP&E

387.0k514.0k
Quarterly
USDQ2, 2017Q3, 2017

Cash

94.0m82.1m

Prepaid Expenses

580.0k596.0k

Current Assets

94.6m82.7m

PP&E

520.0k731.0k
Annual
USDFY, 2015FY, 2016

Net Income

(19.8m)(25.9m)

Depreciation and Amortization

73.0k90.0k

Accounts Payable

1.2m(187.0k)

Cash From Operating Activities

(13.3m)(23.1m)
Quarterly
USDQ2, 2016Q3, 2016Q2, 2017Q3, 2017

Net Income

(11.3m)(17.4m)(18.3m)(30.4m)

Depreciation and Amortization

38.0k60.0k62.0k101.0k

Accounts Payable

846.0k(349.0k)446.0k1.4m

Cash From Operating Activities

(9.8m)(16.2m)(15.1m)(23.9m)
USDFY, 2015

Financial Leverage

-0.2 x
Show all financial metrics

Deciphera Pharmaceuticals Operating Metrics

Aug, 2017

Patent Applications

49

Patents (Foreign)

47

Patents (US)

11
Show all operating metrics

Deciphera Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

B

87/100

SecurityScorecard logo

Deciphera Pharmaceuticals Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Deciphera Pharmaceuticals Online and Social Media Presence

Embed Graph

Deciphera Pharmaceuticals News and Updates

Medison Pharma Enters Exclusive Distribution Agreement with Deciphera Pharmaceuticals to Commercialize QINLOCK® (Ripretinib) in a Multi-Regional Agreement

PETACH TIKVA, Israel and WALTHAM, Mass., Nov. 6, 2020 /PRNewswire/ -- Medison Pharma, a leading international commercial partner for highly innovative therapies, today announced an exclusive distribution agreement with Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) to commercialize...

Thinking about buying stock in Canopy Growth, Deciphera Pharmaceuticals, Genworth Financial, JD.Com, or Tilray?

NEW YORK, Aug. 13, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CGC, DCPH, GNW, JD, and TLRY. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Deciphera Pharmaceuticals stock more than doubles on heavy volume after positive trial data

Shares of Deciphera Pharmaceuticals Inc. more than doubled toward a 14-month high in active premarket trading Tuesday, after the biopharmaceutical company said a phase 3 trial of its treatment of gastrointestinal stromal tumors (GIST) achieved its primary endpoint, paving the way for the company to…

VC-backed Deciphera Pharmaceuticals debuts IPO

Waltham, Massachusetts-based Deciphera Pharmaceuticals, an biotechnology company focused on key mechanisms of tumor drug resistance, has raised $127.5 million for its IPO after pricing its 7.5 million shares at $17 per share. The stock began trading Thursday September 28, 2017 on the NASDAQ under th…

Deciphera Pharmaceuticals Blogs

Rodrigo Ruiz Soto

Rodrigo Ruiz Soto, MD/MSc has served as Vice President of Clinical Development and Translational Medicine since May 2017. Dr. Ruiz Soto is an experienced Clinical Development Hematologist-Oncologist with more than 15 years of experience in Clinical Research. Prior to Deciphera, Dr. Ruiz Soto was Sen…

Matthew L. Sherman, M.D.

Matthew L. Sherman, M.D. is Executive Vice President and Chief Medical Officer of Deciphera Pharmaceuticals. Dr. Sherman brings over 25 years of experience as a physician-scientist in clinical drug development in oncology and hematology at leading biotechnology and pharmaceutical companies. From 200…

Sr. Director, Market Access (Field Leader)

Job #: 03-252 Job Title:  Sr. Director, Market Access (Field Leader) Reports to: Vice President, Market Access Location: Waltham, MA Company Summary: Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients.  We have used our proprieta…

SEC Reporting Manager

Job #: 03-251 Job Title: SEC Reporting Manager Location: Waltham, MA Company Overview: Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients. We have used our proprietary drug discovery platform to develop a diverse pipeline of drug…

Senior Financial Analyst

Job #: 03-250 Job Title:   Senior Financial Analyst    Location: Waltham, MA Company Overview: Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients. We have used our proprietary drug discovery platform to develop a diverse pipeline…

Sr. Commercial Contracts Counsel

Job #: 03-248 Job Title:  Sr. Commercial Contracts Counsel Location: Waltham, MA Company Summary: Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients.  We have used our proprietary drug discovery platform to develop a diverse pipe…
Show more

Deciphera Pharmaceuticals Frequently Asked Questions

  • When was Deciphera Pharmaceuticals founded?

    Deciphera Pharmaceuticals was founded in 2003.

  • Who are Deciphera Pharmaceuticals key executives?

    Deciphera Pharmaceuticals's key executives are Michael D. Taylor, Steven L. Hoerter and Daniel L. Flynn.

  • How many employees does Deciphera Pharmaceuticals have?

    Deciphera Pharmaceuticals has 43 employees.

  • Who are Deciphera Pharmaceuticals competitors?

    Competitors of Deciphera Pharmaceuticals include DemeRx, Closed Loop Medicine and Juvenescence.

  • Where is Deciphera Pharmaceuticals headquarters?

    Deciphera Pharmaceuticals headquarters is located at 10 CityPoint, 500 Totten Pond Rd 6th Floor, Waltham.

  • Where are Deciphera Pharmaceuticals offices?

    Deciphera Pharmaceuticals has offices in Waltham and Lawrence.

  • How many offices does Deciphera Pharmaceuticals have?

    Deciphera Pharmaceuticals has 3 offices.